1096-911X/asset/cover.gif?v=1&s=6770d8cc1200de60f269f1400db9f652983089e0 "Medical and Pediatric Oncology")
This article is a US Government work and, as such, is in the public domain in the United States of America.
1545-5017/asset/MPO_centre.gif?v=1&s=8c0b4c386f6ece3ce7f8c5c02144983ee96bc8b6)
Research Article
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study†
Article first published online: 5 FEB 2002
DOI: 10.1002/mpo.1303
Copyright © 2002 Wiley-Liss, Inc.
Additional Information
How to Cite
Dagher, R., Long, L. M., Read, E. J., Leitman, S. F., Carter, C. S., Tsokos, M., Goletz, T. J., Avila, N., Berzofsky, J. A., Helman, L. J. and Mackall, C. L. (2002), Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study. Med. Pediatr. Oncol., 38: 158–164. doi: 10.1002/mpo.1303
- †
Publication History
- Issue published online: 5 FEB 2002
- Article first published online: 5 FEB 2002
- Manuscript Accepted: 4 SEP 2001
- Manuscript Received: 6 DEC 2000
- Abstract
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , A call to ARMS: targeting thePAX3-FOXO1gene in alveolar rhabdomyosarcoma, Expert Opinion on Therapeutic Targets, 2013, 17, 5, 607
- 2
- 3, , , , , CELL SEPARATION BY COUNTERCURRENT CENTRIFUGAL ELUTRIATION: RECENT DEVELOPMENTS, Preparative Biochemistry and Biotechnology, 2012, 42, 3, 217
- 4, , , , , CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells, International Journal of Cancer, 2012, 131, 4Direct Link:
- 5, , , , Ewing Sarcoma: Biology-Based Therapeutic Perspectives, Pediatric Hematology-Oncology, 2012, 29, 1, 12
- 6, , Sarcomas and the Immune System: Implications for Therapeutic Strategies, Surgical Oncology Clinics of North America, 2012, 21, 2, 341
- You have free access to this content7, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group, Cancer Science, 2012, 103, 9Direct Link:
- 8, , Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma, Sarcoma, 2011, 2011, 1
- 9
- 10, , , , , Nanoparticles: A Promising Modality in the Treatment of Sarcomas, Pharmaceutical Research, 2011, 28, 2, 260
- You have free access to this content11, , , , , , , , Pro-inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8+ T-lymphocyte infiltration and affect tumour progression, The Journal of Pathology, 2011, 223, 3Direct Link:
- 12, , , The long road to immunotherapy for childhood rhabdomyosarcoma, Pediatric Blood & Cancer, 2011, 57, 6Direct Link:
- 13, , Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?, Hematology/Oncology Clinics of North America, 2010, 24, 1, 109
- 14, , , , Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen, Gene Therapy, 2009, 16, 11, 1300
- 15, , , , , , Targets for active immunotherapy against pediatric solid tumors, Cancer Immunology, Immunotherapy, 2009, 58, 6, 831
- 16, , , , , Therapeutic potential of dendritic cell vaccines in sarcoma of the extremities, Expert Review of Anticancer Therapy, 2009, 9, 8, 1065
- 17, , Therapeutic Strategies for Targeting Mononuclear Phagocytes in Cancer, Journal of Pediatric Hematology/Oncology, 2009, 31, 1, 14
- 18, , , , , , , Unusual Sites of Extraskeletal Metastases of Ewing Sarcoma After Allogeneic Hematopoietic Stem Cell Transplantation, Journal of Pediatric Hematology/Oncology, 2009, 31, 2, 142
- 19, , , Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma, Pediatric Blood & Cancer, 2008, 51, 1Direct Link:
- 20, , Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?, Pediatric Clinics of North America, 2008, 55, 1, 147
- 21, , , , , , , , , , , , Clonal T-cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA-A*0206, Journal of Orthopaedic Research, 2008, 26, 2Direct Link:
- 22, , Ewing sarcoma: prognostic criteria, outcomes and future treatment, Expert Review of Anticancer Therapy, 2008, 8, 4, 617
- 23, , , , , , , , , , , , , Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma, Cancer Science, 2008, 99, 2Direct Link:
- 24, Adult human sarcomas. II. Medical oncology, Expert Review of Anticancer Therapy, 2007, 7, 2, 183
- 25
- 26, , , , , , , , , , , Low-dose Interleukin-2 Administered Pre-operatively to Patients with Gastric Cancer Activates Peripheral and Peritumoral Lymphocytes But Does Not Affect Prognosis, Annals of Surgical Oncology, 2007, 14, 4, 1295
- 27, , , , Adult soft tissue sarcomas: Conventional therapies and molecularly targeted approaches, Cancer Treatment Reviews, 2006, 32, 1, 9
- 28, Future directions for immunotherapeutic intervention against sarcomas, Current Opinion in Oncology, 2006, 18, 4, 363
- 29, , GENETICS OF SOFT TISSUE TUMORS, Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 1, 435
- 30, , , , Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma, Anti-Cancer Drugs, 2006, 17, 1, 1
- 31, , MYCNderegulation as a potential target for novel therapies in rhabdomyosarcoma, Expert Review of Anticancer Therapy, 2006, 6, 2, 217
- 32, , , , , , , , , , , , , Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5, Cancer Science, 2006, 97, 12Direct Link:
- 33, , , Current treatment for Ewing’s sarcoma, Expert Review of Anticancer Therapy, 2005, 5, 2, 319
- 34, , , , Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma, Cancer Immunology, Immunotherapy, 2005, 54, 6, 526
- 35, , , , , , , , , , , Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma, Pediatric Transplantation, 2005, 9, 5Direct Link:
- 36, 2005,
- 37, , Ewing sarcoma: The pediatrician's point of view, Pediatric Blood & Cancer, 2004, 42, 5Direct Link:
- 38, , , , , , , , , , , NOVEL APPROACH TO IMMUNOTHERAPY FOR EPITHELIAL CANCERS, BONE AND SOFT-TISSUE SARCOMAS, Annals of Cancer Research and Therapy, 2004, 12, 1/2, 53
- 39, , , , , , , , Phase I/II Trial of Autologous Tumor Cell Line–Derived Vaccines for Recurrent or Metastatic Sarcomas, Cancer Biotherapy & Radiopharmaceuticals, 2004, 19, 5, 581
- 40
- 41, , , , Thérapie cellulaire dans le traitement du cancer de l’enfant, Archives de Pédiatrie, 2004, 11, 2, 130
- 42
- 43, New Therapeutic strategies for soft tissue sarcomas, Current Treatment Options in Oncology, 2003, 4, 6, 441
- 44
- 45, 2003,
- 46
- 47, , Soft Tissue Sarcoma,Direct Link: